Noumed Pharmaceuticals Pty Limited Pharmaceutical Import Profile — Australia (DGFT 2022–2026)

Name: Noumed Pharmaceuticals Pty Limited Pharmaceutical Import Records from India — 5 Products, $4.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Noumed Pharmaceuticals Pty Limited — Pharmaceutical Importer Profile (2026) | 5 Products, $4.2M Trade | TransData Nexus

Noumed Pharmaceuticals Pty Limited

Pharmaceutical Importer · Australia · Antihistamines & Allergy Focus · $4.2M Total Trade · DGFT Verified

Noumed Pharmaceuticals Pty Limited is a pharmaceutical importer based in Australia with a total trade value of $4.2M across 5 products in 5 therapeutic categories. Based on 344 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Noumed Pharmaceuticals Pty Limited sources from 6 verified Indian suppliers, with Lyrus Life Sciences Private Limited accounting for 49.6% of imports.

Noumed Pharmaceuticals Pty Limited — Import Portfolio & Supplier Network

Noumed Pharmaceuticals Pty Limited import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Noumed Pharmaceuticals Pty Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lyrus Life Sciences Private Limited	$2.5M	135	49.6%
Cipla Limited	$1.2M	299	25.0%
Gracure Pharmaceuticals Limited

What Formulations Does Noumed Pharmaceuticals Pty Limited Import?

Formulation	Value	Ships
Priceline pharmacy paraosteo 665MG	$400.0K	8
Noumed bisoprolol 5MG tablets 2x14's	$108.2K	3
Clotrimazole 1% 10MG/g anti fungal	$108.0K	7
Noumed olanzapine 2.5 MG TAB's 2x14's	$107.5K	3
Noumed olanzapine 5 MG TAB's 2x14's	$105.2K	3
Noumed olanzapine 7.5 MG TAB's 2x14'	$104.3K	3
Noumed sertraline 50MG tablets 30's	$104.3K	3
Noumed olanzapine 10 MG TAB's 2x14's	$104.0K	3
Noumed telmisartan 40MG tablets 28's	$103.9K	3
Noumed candesartan 16MG TAB's 2x15's	$103.5K	3
Noumed telmisartan 80MG tablets 28's	$103.4K	3
Noumed sertraline 100MG tablets 30's	$103.3K	3
Noumed sildenafil 100MG tablets 1x4's	$103.1K	3
Terrywhite chemmart paraosteo 665MG	$100.0K	2
Noumed clarithomycin 250MG tablets	$93.2K	2

Noumed Pharmaceuticals Pty Limited imports 292 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fexofenadine	Antihistamines & Allergy	$2.8M	247	2.5%	9
2	Clotrimazole	Antifungals	$643.4K	58	0.7%	18
3	Docusate	Gastrointestinal	$320.9K	22	1.9%	6
4	Bisoprolol	Cardiovascular	$300.0K	6	0.4%	12
5	Bromhexine	Respiratory & OTC	$153.6K	11	0.9%	15

Noumed Pharmaceuticals Pty Limited imports 5 pharmaceutical products across 5 categories into Australia totaling $4.2M.

Noumed Pharmaceuticals Pty Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Noumed Pharmaceuticals Pty Limited is an Australian private pharmaceutical company specializing in the development, manufacturing, and marketing of generic label pharmaceutical products. Established in August 2020, the company is headquartered in Adelaide, South Australia. Noumed Pharmaceuticals is committed to enhancing the quality of healthcare by providing a diverse range of high-quality, affordable medicines. The company is on a mission to manufacture onshore by 2026, with plans to invest $100 million in local manufacturing capabilities.

In addition to its manufacturing and marketing operations, Noumed Pharmaceuticals has developed a robust distribution network. In June 2025, the company relocated to a new, purpose-built, state-of-the-art manufacturing and warehouse facility located in the Nexus North Industrial Estate, Salisbury South, Adelaide. This 6,000 square meter, temperature-controlled warehouse has a 10,000-pallet capacity and is fully operational. The company is also in the final stages of planning a 20,000 square meter manufacturing facility to further support its onshore manufacturing goals.

2Distribution Network

Noumed Pharmaceuticals operates a comprehensive distribution network within Australia, centered around its advanced manufacturing and warehouse facility in Adelaide. The 6,000 square meter, temperature-controlled warehouse, with a 10,000-pallet capacity, serves as the primary hub for the company's logistics operations. This facility is strategically located to facilitate efficient distribution across the Australian market. The company is also in the process of establishing a 20,000 square meter manufacturing facility, which will further enhance its production and distribution capabilities.

3Industry Role

Noumed Pharmaceuticals Pty Limited functions as a pharmaceutical manufacturer and distributor within Australia's supply chain. The company is actively involved in the production and marketing of generic pharmaceutical products, aiming to provide high-quality, affordable medicines to the Australian market. While the company imports certain pharmaceutical formulations, it is also focused on developing its own manufacturing capabilities to reduce reliance on imports and strengthen its position in the domestic market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Noumed Pharmaceuticals Pty Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Noumed Pharmaceuticals has established relationships with several Indian pharmaceutical suppliers, with a significant portion of its imports originating from India. The company's total import value from India amounts to $4.2 million USD, encompassing 344 shipments across five therapeutic categories. The top five imported products include Fexofenadine ($2.8 million, 66.3% share), Clotrimazole ($643,000, 15.3% share), Docusate ($321,000, 7.6% share), Bisoprolol ($300,000, 7.1% share), and Bromhexine ($154,000, 3.7% share). The primary suppliers from India are LYRUS LIFE SCIENCES PRIVATE LIMITED ($2.5 million, 49.6% share) and CIPLA LIMITED ($1.2 million, 25.0% share). This indicates a high level of concentration in sourcing, with the top two suppliers accounting for 74.6% of the total import value.

The concentration in sourcing suggests that Noumed Pharmaceuticals may face risks associated with supplier dependency, such as potential disruptions in supply chains or price fluctuations. However, the company's strategic choice to import from established suppliers like LYRUS LIFE SCIENCES and CIPLA LIMITED may also reflect a focus on product quality and reliability. The stability of these relationships is crucial for maintaining a consistent supply of pharmaceutical products.

2Supply Chain Resilience

Noumed Pharmaceuticals' supply chain resilience is influenced by its sourcing strategy from Indian suppliers. The company's reliance on a limited number of suppliers, particularly LYRUS LIFE SCIENCES PRIVATE LIMITED and CIPLA LIMITED, may expose it to risks such as supply disruptions or geopolitical factors affecting trade between Australia and India. To mitigate these risks, Noumed Pharmaceuticals could consider diversifying its supplier base and establishing relationships with additional manufacturers. Additionally, increasing the diversity of imported formulations and exploring alternative shipping routes could enhance supply chain resilience. Ensuring that key suppliers comply with international Good Manufacturing Practice (GMP) standards is essential for maintaining product quality and regulatory compliance.

Importing Pharmaceuticals into Australia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Australia

1Regulatory Authority & Framework

In Australia, the regulation of therapeutic goods, including pharmaceuticals, is overseen by the Therapeutic Goods Administration (TGA), a division of the Department of Health and Aged Care. The TGA is responsible for ensuring that therapeutic goods are safe, effective, and of high quality before they can be supplied in Australia. The primary legislation governing the regulation of therapeutic goods is the Therapeutic Goods Act 1989, which establishes a national system of controls relating to the quality, safety, efficacy, and timely availability of therapeutic goods used in Australia or exported from Australia. (tga.gov.au)

The Therapeutic Goods Regulations 1990 provide detailed requirements related to the manufacturing, supply, and advertising of therapeutic goods in Australia. These regulations set out important elements of the therapeutic goods regulatory scheme, including specifying fees for applying for marketing approval for a therapeutic good or for a manufacturing license, and setting out exemptions from the requirement for therapeutic goods other than medical devices to be included in the Australian Register of Therapeutic Goods (ARTG). (tga.gov.au)

2Import Licensing & GMP

To import therapeutic goods into Australia, companies must comply with the requirements set out by the TGA. Generally, therapeutic goods must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported into Australia, unless they are exempt from being entered in the ARTG. Every ARTG entry belongs to a 'sponsor' who is responsible for applying for and maintaining the ARTG entry. (tga.gov.au)

Noumed Pharmaceuticals Pty Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Noumed Pharmaceuticals' product strategy focuses on importing and manufacturing generic pharmaceutical products across five therapeutic categories: Antihistamines & Allergy, Antifungals, Gastrointestinal, Cardiovascular, and Respiratory. The company's top five imported products include Fexofenadine (66.3% share), Clotrimazole (15.3% share), Docusate (7.6% share), Bisoprolol (7.1% share), and Bromhexine (3.7% share). This product mix indicates a strategic emphasis on addressing common health concerns such as allergies, fungal infections, gastrointestinal issues, cardiovascular conditions, and respiratory ailments. The market demand for these therapeutic areas is driven by the prevalence of these conditions in the Australian population and the need for accessible, cost-effective treatment options.

2Sourcing Profile

Noumed Pharmaceuticals' sourcing strategy involves importing finished pharmaceutical formulations from India, focusing on generic products that meet the company's quality standards. The company imports a diverse range of formulations, with a total of 292 unique formulations across five therapeutic categories. This approach allows Noumed Pharmaceuticals to offer

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Noumed Pharmaceuticals Pty Limited

What products does Noumed Pharmaceuticals Pty Limited import from India?

Noumed Pharmaceuticals Pty Limited imports 5 pharmaceutical products across 5 categories. Top imports: Fexofenadine ($2.8M), Clotrimazole ($643.4K), Docusate ($320.9K), Bisoprolol ($300.0K), Bromhexine ($153.6K).

Who supplies pharmaceuticals to Noumed Pharmaceuticals Pty Limited from India?

Noumed Pharmaceuticals Pty Limited sources from 6 verified Indian suppliers. The primary supplier is Lyrus Life Sciences Private Limited (49.6% of imports, $2.5M).

What is Noumed Pharmaceuticals Pty Limited's total pharmaceutical import value?

Noumed Pharmaceuticals Pty Limited's total pharmaceutical import value from India is $4.2M, based on 344 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Noumed Pharmaceuticals Pty Limited focus on?

Noumed Pharmaceuticals Pty Limited imports across 5 categories. The largest: Antihistamines & Allergy (66.3%), Antifungals (15.3%), Gastrointestinal (7.6%).

Get Full Noumed Pharmaceuticals Pty Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.